IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-42883-2.html
   My bibliography  Save this article

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

Author

Listed:
  • Xijiao Ren

    (Chongqing University)

  • Zhuo Cheng

    (Chongqing University)

  • Jinming He

    (Chongqing University)

  • Xuemei Yao

    (Chongqing University)

  • Yingqi Liu

    (Chongqing University)

  • Kaiyong Cai

    (Chongqing University)

  • Menghuan Li

    (Chongqing University)

  • Yan Hu

    (Chongqing University)

  • Zhong Luo

    (Chongqing University)

Abstract

Immune-checkpoint inhibitors (ICI) are promising modalities for treating triple negative breast cancer (TNBC). However, hyperglycolysis, a hallmark of TNBC cells, may drive tumor-intrinsic PD-L1 glycosylation and boost regulatory T cell function to impair ICI efficacy. Herein, we report a tumor microenvironment-activatable nanoassembly based on self-assembled aptamer-polymer conjugates for the targeted delivery of glucose transporter 1 inhibitor BAY-876 (DNA-PAE@BAY-876), which remodels the immunosuppressive TME to enhance ICI response. Poly β-amino ester (PAE)-modified PD-L1 and CTLA-4-antagonizing aptamers (aptPD-L1 and aptCTLA-4) are synthesized and co-assembled into supramolecular nanoassemblies for carrying BAY-876. The acidic tumor microenvironment causes PAE protonation and triggers nanoassembly dissociation to initiate BAY-876 and aptamer release. BAY-876 selectively inhibits TNBC glycolysis to deprive uridine diphosphate N-acetylglucosamine and downregulate PD-L1 N-linked glycosylation, thus facilitating PD-L1 recognition of aptPD-L1 to boost anti-PD-L1 therapy. Meanwhile, BAY-876 treatment also elevates glucose supply to tumor-residing regulatory T cells (Tregs) for metabolically rewiring them into an immunostimulatory state, thus cooperating with aptCTLA-4-mediated immune-checkpoint inhibition to abolish Treg-mediated immunosuppression. DNA-PAE@BAY-876 effectively reprograms the immunosuppressive microenvironment in preclinical models of TNBC in female mice and provides a distinct approach for TNBC immunotherapy in the clinics.

Suggested Citation

  • Xijiao Ren & Zhuo Cheng & Jinming He & Xuemei Yao & Yingqi Liu & Kaiyong Cai & Menghuan Li & Yan Hu & Zhong Luo, 2023. "Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-42883-2
    DOI: 10.1038/s41467-023-42883-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-42883-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-42883-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Sahil Inamdar & Abhirami P. Suresh & Joslyn L. Mangal & Nathan D. Ng & Alison Sundem & Christopher Wu & Kelly Lintecum & Abhirami Thumsi & Taravat Khodaei & Michelle Halim & Nicole Appel & Madhan Moha, 2023. "Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Qin Wu & Wail ba-alawi & Genevieve Deblois & Jennifer Cruickshank & Shili Duan & Evelyne Lima-Fernandes & Jillian Haight & Seyed Ali Madani Tonekaboni & Anne-Marie Fortier & Hellen Kuasne & Trevor D. , 2020. "GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer," Nature Communications, Nature, vol. 11(1), pages 1-12, December.
    3. Roberta Zappasodi & Inna Serganova & Ivan J. Cohen & Masatomo Maeda & Masahiro Shindo & Yasin Senbabaoglu & McLane J. Watson & Avigdor Leftin & Rachana Maniyar & Svena Verma & Matthew Lubin & Myat Ko , 2021. "CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours," Nature, Nature, vol. 591(7851), pages 652-658, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Xinyu Tang & Xinrui Mao & Peiwen Ling & Muxin Yu & Hua Pan & Jiaming Wang & Mingduo Liu & Hong Pan & Wen Qiu & Nan Che & Kai Zhang & Feifan Bao & Hongwei Peng & Qiang Ding & Shui Wang & Wenbin Zhou, 2024. "Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    2. Zhenxing Zhang & Xin Li & Fan Yang & Chao Chen & Ping Liu & Yi Ren & Pengkai Sun & Zixiong Wang & Yongping You & Yi-Xin Zeng & Xinjian Li, 2021. "DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    3. Nils-Petter Rudqvist & Maud Charpentier & Claire Lhuillier & Erik Wennerberg & Sheila Spada & Caroline Sheridan & Xi Kathy Zhou & Tuo Zhang & Silvia C. Formenti & Jennifer S. Sims & Alicia Alonso & Sa, 2023. "Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors," Nature Communications, Nature, vol. 14(1), pages 1-23, December.
    4. Xijiao Ren & Rui Xue & Yan Luo & Shuang Wang & Xinyue Ge & Xuemei Yao & Liqi Li & Junxia Min & Menghuan Li & Zhong Luo & Fudi Wang, 2024. "Programmable melanoma-targeted radio-immunotherapy via fusogenic liposomes functionalized with multivariate-gated aptamer assemblies," Nature Communications, Nature, vol. 15(1), pages 1-24, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-42883-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.